Trial Profile
A Phase I/II Study of the c-Met Inhibitor Cabozantinib as a Targeted Strategy to Reverse Resistance to the Proteasome Inhibitor Carfilzomib in Refractory Multiple Myeloma
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 12 Sep 2023
Price :
$35
*
At a glance
- Drugs Cabozantinib (Primary) ; Carfilzomib; Dexamethasone; Dexamethasone
- Indications Multiple myeloma; Plasmacytoma
- Focus Adverse reactions; Therapeutic Use
- 26 May 2021 Status changed from recruiting to discontinued.
- 24 Jun 2020 Planned End Date changed from 1 Oct 2021 to 1 Oct 2022.
- 24 Jun 2020 Planned primary completion date changed from 1 Oct 2020 to 1 Oct 2021.